Wolverine Stack
BPC-157 + TB-500 | Tissue Repair & Recovery Protocol
The Wolverine Stack combines BPC-157 (Body Protection Compound-157) and TB-500 (Thymosin Beta-4 fragment) for enhanced tissue repair and recovery. Named after the Marvel character known for regenerative abilities, this combination targets complementary healing pathways: BPC-157 increases actin production and promotes angiogenesis via nitric oxide modulation, while TB-500 binds actin to facilitate cell migration and reduce scarring. A 2021 clinical study showed 87.5% of patients experienced knee pain relief using BPC-157 alone or in combination with TB-4.
Daily dose
BPC-157: 250-500mcg + TB-500: 2-2.5mg
Frequency
BPC-157: 1-2x daily, TB-500: 2x weekly
Cycle length
4-8 weeks
Storage
2-8°C (reconstituted)
Key benefits
Combines complementary healing mechanisms: BPC-157 promotes angiogenesis and reduces inflammation while TB-500 enhances cell migration and reduces scarring. Clinical study showed 87.5% improvement in knee pain patients.
How it works
BPC-157 increases actin production at gene level and modulates nitric oxide for vascular effects. TB-500 is an actin-binding protein that sequesters actin for cell migration. Together they enhance fibroblast and immune cell movement to injury sites through synergistic actin regulation.
Dosage protocols
Goal
General Recovery Protocol
Dose
BPC-157: 250mcg 2x/day + TB-500: 2mg 2x/week · BPC-157 daily, TB-500 twice weekly
Route
Subcutaneous
Goal
Intensive Injury Recovery
Dose
BPC-157: 500mcg 2x/day + TB-500: 2.5mg 2x/week · BPC-157 daily, TB-500 twice weekly
Route
Subcutaneous near injury site
Goal
Maintenance/Prevention Protocol
Dose
BPC-157: 250mcg 1x/day + TB-500: 2mg 1x/week · BPC-157 daily, TB-500 weekly
Route
Subcutaneous
Goal
Localized Joint Protocol
Dose
Per clinical guidance - based on Lee & Padgett study · As directed by practitioner
Route
Intra-articular (clinical setting only)
Research indications
tissue Repair
wound Healing
anti Inflammatory
Administration
Interactions
Safety notes
Not FDA approved - research chemical only
Contraindicated with ANY history of cancer or suspicious growths
Banned by WADA and major sports organizations
Limited human safety data - most research is preclinical
Do not combine with chemotherapy or in active malignancy
Monitor for unusual tissue growth or changes
Not recommended during pregnancy or breastfeeding
Consult healthcare provider before use, especially with existing conditions
Research studies
BPC-157 Systematic Review (Vasireddi et al., 2025)
Systematic Review | 36 articles | Orthopedic sports medicine focus
Comprehensive review of BPC-157 in orthopedics. Preclinical models showed improvements in muscle tears, tendon ruptures, ligament tears, and fracture healing. Mechanism involves enhanced GH receptor expression and angiogenesis with reduced inflammatory cytokines.
View study →BPC-157 + TB4 Knee Pain Study (Lee & Padgett, 2021)
Human | 16 patients | Intra-articular injection | Retrospective review
First published study combining BPC-157 and thymosin beta-4. Overall 87.5% (14/16) experienced knee pain relief. BPC-157 alone: 91.6% improvement (11/12). BPC-157 + TB4 combination: 75% improvement (3/4). Suggests intra-articular BPC-157 helps multiple types of knee pain.
View study →Thymosin β4 Clinical Wound Healing (Treadwell et al., 2012)
Human Phase 2 | Stasis and pressure ulcers | Accelerated healing
In two Phase 2 clinical trials, thymosin β4 accelerated wound healing by approximately one month in patients with stasis and pressure ulcers who responded to treatment.
View study →Thymosin β4 Regenerative Properties Review (Goldstein et al., 2012)
Review | Multi-functional peptide | Clinical applications
Comprehensive review establishing thymosin β4 as a regenerative peptide that promotes cell migration, reduces inflammation and apoptosis, and decreases scar formation. Clinical trials ongoing for dermal wounds, corneal injuries, cardiac and CNS repair.
View study →BPC-157 Achilles Tendon Healing (2003)
Rats | 10 μg/kg i.p. daily | 14 days | Improved biomechanics
BPC-157 demonstrated superior healing of transected Achilles tendons with improved biomechanical properties, faster functional recovery, and enhanced tendon-to-bone integration.
View study →Thymosin β4 Wound Healing Acceleration (1999)
Rats | Full thickness wounds | 42-61% faster re-epithelialization
Addition of Tβ4 topically or intraperitoneally increased re-epithelialization by 42% at 4 days and up to 61% at 7 days post-wounding, with increased collagen deposition and angiogenesis.
View study →